Insulin reverses impaired acetylcholine-induced dilatation of the rat basilar artery during diabetes mellitus.
The goal of this study was to determine whether treatment of diabetic rats with insulin reverses impaired nitric oxide synthase-dependent reactivity of the basilar artery in vivo. We measured the diameter of the basilar artery in non-diabetic rats, diabetic (streptozotocin; 50-60 mg/kg i.p.) rats, and diabetic rats treated with insulin implants in response to acetylcholine and nitroglycerin before and following topical application of N(G)-monomethyl-L-arginine (L-NMMA). Reactivity of the basilar artery was measured 2-3 months after injection of streptozotocin. We found that topical application of acetylcholine (1.0 and 10 microM) produced dose-related dilatation of the basilar artery in non-diabetic rats, which was inhibited (>80%) by topical application of L-NMMA (10 microM). In diabetic rats, the magnitude of vasodilation produced by acetylcholine was significantly less than in non-diabetic rats. Further, topical application of L-NMMA did not affect dilatation of the basilar artery in diabetic rats in response to acetylcholine. In insulin treated diabetic rats, dilatation of the basilar artery in response to acetylcholine was significantly greater than that observed in either non-diabetic or diabetic rats. In contrast, dilatation of the basilar artery in response to nitroglycerin was similar in insulin treated diabetic rats, non-diabetic rats and diabetic rats. Topical application of L-NMMA only partially inhibited dilatation of the basilar artery in response to acetylcholine in diabetic rats treated with insulin. Thus, the findings of this study suggest that impaired acetylcholine-induced dilatation of the basilar artery during diabetes mellitus can be restored by treatment with insulin. Further, it appears that the contribution of cellular pathways, in addition to nitric oxide synthase, may contribute to dilatation of the basilar artery in response to acetylcholine in rats treated with insulin.
Department of Physiology and Biophysics, University of Nebraska Medical Center, 984575 Nebraska Medical Center, Omaha, NE 68198-4575, USA. wgmayhan@unmc.edu
W G
WG
Mayhan
A K
AK
Trauernicht
S D
SD
Irvine
D000109:Acetylcholine / Q000008:administration & dosage*; D000287:Administration, Topical; D000818:Animals; D001488:Basilar Artery / Q000187:drug effects* / Q000503:physiopathology; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D005996:Nitroglycerin / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D007507:Therapeutic Irrigation; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage; D019323:omega-N-Methylarginine / Q000008:administration & dosage
D001786:Blood Glucose; D004343:Drug Implants; D004791:Enzyme Inhibitors; D007328:Insulin; D014665:Vasodilator Agents; D019323:omega-N-Methylarginine; D013311:Streptozocin; D005996:Nitroglycerin; D000109:Acetylcholine